[go: up one dir, main page]

BR112012007888A2 - "métodos de tratamento usando anticorpos anti-ldl oxidada". - Google Patents

"métodos de tratamento usando anticorpos anti-ldl oxidada".

Info

Publication number
BR112012007888A2
BR112012007888A2 BR112012007888A BR112012007888A BR112012007888A2 BR 112012007888 A2 BR112012007888 A2 BR 112012007888A2 BR 112012007888 A BR112012007888 A BR 112012007888A BR 112012007888 A BR112012007888 A BR 112012007888A BR 112012007888 A2 BR112012007888 A2 BR 112012007888A2
Authority
BR
Brazil
Prior art keywords
methods
treatment
ldl antibodies
oxidized anti
oxidized
Prior art date
Application number
BR112012007888A
Other languages
English (en)
Inventor
Frendeus Björn
Grove Kevin
Van Bruggen Nick
Carlsson Roland
Bullens Sherron
Glazer Steven
Bunting Stuart
Original Assignee
Bioinvent Int
Genentech Inc
Univ Oregon Health & Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioinvent Int, Genentech Inc, Univ Oregon Health & Science filed Critical Bioinvent Int
Publication of BR112012007888A2 publication Critical patent/BR112012007888A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

métodos de tratamento usando anti-corpos anti-ldl oxidada. a presente invenção refere-se a métodos e composições para aumentar a sensibilidade à insulina, compreendendo a administração de anticorpos anti-ldl oxidada.
BR112012007888A 2009-08-28 2010-08-27 "métodos de tratamento usando anticorpos anti-ldl oxidada". BR112012007888A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23811409P 2009-08-28 2009-08-28
PCT/US2010/047030 WO2011025978A2 (en) 2009-08-28 2010-08-27 Methods of treatment using anti-oxidized ldl antibodies

Publications (1)

Publication Number Publication Date
BR112012007888A2 true BR112012007888A2 (pt) 2019-09-24

Family

ID=43628682

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012007888A BR112012007888A2 (pt) 2009-08-28 2010-08-27 "métodos de tratamento usando anticorpos anti-ldl oxidada".

Country Status (12)

Country Link
US (1) US20110256134A1 (pt)
EP (1) EP2470210A2 (pt)
JP (1) JP2013503195A (pt)
KR (1) KR20120111724A (pt)
CN (1) CN102711823A (pt)
AU (1) AU2010286532A1 (pt)
BR (1) BR112012007888A2 (pt)
CA (1) CA2772380A1 (pt)
IL (1) IL218359A0 (pt)
MX (1) MX2012002459A (pt)
SG (1) SG178596A1 (pt)
WO (1) WO2011025978A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR076640A1 (es) * 2009-03-06 2011-06-29 Genentech Inc Formulacion con anticuerpo. metodo para estabilizar anticuerpo. articulo de manufactura
US9221876B2 (en) 2011-11-11 2015-12-29 Cardiovax, Llc Methods for treating kidney disease with fragments of ApoB-100
RU2495048C1 (ru) * 2012-04-18 2013-10-10 Андрей Валентинович Исаев Пептид, обладающий антиатеросклеротическим действием и композиция для профилактики и лечения атеросклероза сосудов
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
WO2017210360A1 (en) 2016-05-31 2017-12-07 Cardiovax, Llc Methods for diagnosing and treating systemic lupus erythematosus
WO2019215300A1 (en) 2018-05-09 2019-11-14 Medirista Biotechnologies Ab Antibodies for use in combination therapy
AU2019279883B2 (en) * 2018-05-29 2025-05-22 Abcentra, Llc Compositions and methods for treatment of psoriasis
EP4192883A4 (en) * 2020-08-05 2024-12-04 Crystal Bioscience Inc. Anti-tigit antibody and methods of use thereof
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014359A1 (en) * 2001-03-16 2004-02-19 Thomas Jefferson University Regulation of apob in treatment and drug screening for cardiovascular and metabolic disorders or syndromes
ES2299602T3 (es) * 2001-10-04 2008-06-01 Toray Industries, Inc. Sustancia hidrofilica y procedimiento de obtencion de la misma.
SE0302312D0 (sv) * 2002-10-04 2003-08-27 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
SE0202959D0 (sv) * 2002-10-04 2002-10-04 Forskarpatent I Syd Ab Ideon Peptide-Base passive immunization therapy for treatment of atherosclerosis
WO2008104194A1 (en) * 2007-02-28 2008-09-04 Bioinvent International Ab Oxidized ldl and antibodies thereto for the treatment of atheroscleroti c plaques

Also Published As

Publication number Publication date
KR20120111724A (ko) 2012-10-10
JP2013503195A (ja) 2013-01-31
WO2011025978A3 (en) 2011-04-21
WO2011025978A2 (en) 2011-03-03
CN102711823A (zh) 2012-10-03
IL218359A0 (en) 2012-04-30
AU2010286532A1 (en) 2012-04-12
CA2772380A1 (en) 2011-03-03
US20110256134A1 (en) 2011-10-20
SG178596A1 (en) 2012-04-27
AU2010286532A8 (en) 2012-08-16
MX2012002459A (es) 2012-08-08
EP2470210A2 (en) 2012-07-04

Similar Documents

Publication Publication Date Title
BR112012007888A2 (pt) "métodos de tratamento usando anticorpos anti-ldl oxidada".
CY1122278T1 (el) Αντι il-36r αντισωματα
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
MX2010006823A (es) Metodos para el tratamiento de la gota.
DK2148670T3 (da) Titrering af tapentadol
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
CR20130016A (es) ANTICUERPOS PEPTIDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
EA201290919A1 (ru) Индазольные соединения и их применение
BR112012032778A2 (pt) "proteínas multiespecíficas e multivalentes"
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
ATE511845T1 (de) Verwendung von isothicyanat-derviaten als myelom- bekämpfende wirkstoffe
DK2459216T3 (da) Immunogene sammensætninger omfattende tlr-aktivitetsmodulatorer
MX2012007098A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
ECSP10010295A (es) Formulacion de anticuerpo
MX2012007161A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
CR20120577A (es) Anticuerpos hacia gdf8 humano
AU2011274619A8 (en) miRNA and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated BRAF pathway
BR112014009866A2 (pt) formulações de anticorpos e métodos
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
BR112014005935A2 (pt) derivados de anilina, sua preparação e sua aplicação terapêutica
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
UA113849C2 (xx) Застосування сигма-лігандів при болю, пов'язаному з діабетом 2 типу
BR112012026707A2 (pt) uso de um anticorpo anti-cd20 afucosilado, composição que compreende um anticorpo anti-cd20 afucosilado e método de tratamento de pacientes que sofrem de câncer por meio da administração de um anticorpo anti-cd20 afucosilado
EP2575639A4 (en) SAFETY PIN ARRANGEMENT

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.